An observational study in Heart Failure (HF), sponsored by Yan'an Affiliated Hospital of Kunming Medical University. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-20.
Sponsored by Yan'an Affiliated Hospital of Kunming Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 377 studies in Heart Failure with a site in China — 162 open to participants now, 182 under way, 18 of them phase 3. Heart Failure · China.
Among the 377 studies in Heart Failure with a site in China, this one is the 119th largest by planned enrollment of the 130 observational ones that give a count, is one of 43 that started in 2026, is one of 130 observational ones, reaches primary completion later than 75 of the 181 other live ones, and was the 338th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →162 of the 377 studies in Heart Failure with a site in China are open now. Recruiting first, the newest first:
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 65+
Jiangsu Taizhou People's Hospital · Sites in China
Ages 65+ · Healthy volunteers
AstraZeneca · Sites in China, United States, Argentina and 29 more countries
Ages 18+
Pulnovo Medical, Inc. · Sites in China, United States
Ages 18–85
Tasly Pharmaceutical Group Co., Ltd · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
377 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 44 · Phase 3 49 · Phase 4 30
First in 1983; this study’s year is marked. 43 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 130 across the 247 interventional studies, 554 across the 130 observational. Of the 117 that completed or were terminated, 33 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
109 of 377 have an industry lead sponsor. The 10 most frequent:
Yan'an Affiliated Hospital of Kunming Medical University is the lead sponsor of 9 studies on the registry; 5 are open to participants now.
Yan'an Affiliated Hospital of Kunming Medical University has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
47 of the studies in Heart Failure with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT07496372Phase 3HELP Therapeutics Co., Ltd.A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV) | 2027-06-30 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06024746Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) | 2027-11 |
| NCT06927440Shanghai Jiao Tong University School of MedicineNational Multicenter Registry for Pediatric End-Stage Heart Failure in China | 2026-11-30 |
Add all 47 to your calendar (.ics) → With an account.
Among the 377 studies in Heart Failure with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
At different stages of heart failure (HF), the cardiac and cerebral oxygen reserve exhibits varying degrees of decline due to chronic hypoxia and microvascular dysfunction caused by reduced cardiac output, leading to cognitive dysfunction. As a direct marker of microvascular function, early identification and intervention of cardiac and cerebral oxygen reserve are crucial to prevent irreversible damage to organs such as the heart and brain. However, there is currently no precise and effective method to quantify cardiac and cerebral oxygen reserve. Oxygen-sensitive magnetic resonance imaging (OS-MRI), as an emerging functional imaging technique, can dynamically monitor oxygenation changes and oxygen reserve capacity in Homo sapiens tissues. However, due to its technical complexity, its application in combined cardiac and cerebral assessment in HF patients remains underexplored.
This prospective, single-center cohort study employs OS-MRI combined with respiratory maneuvers to examine the heart and brain in HF patients at different stages. Continuous image acquisition is performed during hyperventilation to breath-holding, and myocardial oxygen reserve (MORE) and cerebral oxygen reserve (CORE) are derived using MATLAB and CVI42 post-processing software. Cognitive function is assessed using the Montreal Cognitive Assessment (MoCA) scale, with scores \<26 indicating mild cognitive dysfunction. Subsequently, SPSS is used to analyze the correlation between cardiac/cerebral oxygen reserve and MoCA scores, providing imaging-based evidence for early clinical detection of oxygen reserve decline in HF patients and confirming the potential link between cardiac/cerebral oxygen reserve, HF, and cognitive dysfunction.
Heart failure (Heart Failure, HF) is a complex clinical syndrome often caused by structural abnormalities in the heart (Broussonetia papyrifera) and functional impairments (Parazacco spilurus subsp. spilurus). Its high incidence and rehospitalization rates have become a major global public health burden. In addition to typical symptoms such as dyspnea, fatigue, and fluid retention, growing evidence indicates that HF patients commonly exhibit varying degrees of cognitive dysfunction, spanning domains such as executive function, memory, and information processing speed. This not only severely impacts patients' quality of life and treatment adherence but also serves as an independent predictor of poor prognosis, highlighting the urgency of clinical management for "cardio-cerebral comorbidity." Cardio-cerebral oxygen reserve, which evaluates the intrinsic potential of the heart and brain-two core organs-to maintain oxygen supply and functional stability under physiological stress, serves as a key physiological bridge linking cardiac insufficiency and cerebral injury. Currently, multiple hypotheses attempt to explain the pathological mechanisms by which HF leads to cognitive decline, including chronic cerebral hypoperfusion, persistent overactivation of the neurohumoral system, systemic endothelial dysfunction, and the resulting oxidative stress and microvascular damage. However, how these mechanisms specifically affect the oxygen metabolism balance between the heart and brain in HF patients, as well as the precise role of cardio-cerebral oxygen reserve in this process, remains unclear. This limits our systemic understanding of heart-brain interactions from a holistic perspective and hinders the development of related therapeutic strategies.
On the technical front, oxygen-sensitive magnetic resonance imaging (OS-MRI) has emerged as a non-invasive imaging modality capable of directly and quantitatively assessing oxygenated status in tissue microcirculation through the blood oxygen level-dependent (BOLD) effect, offering a unique perspective for evaluating organ oxygen reserve. Although this technique has demonstrated potential in studies of macrovascular and coronary artery diseases, as well as myocardial microvascular dysfunction in HF with preserved ejection fraction (HFpEF), its application in synchronously and integratively assessing cardiac and cerebral oxygen responses in the same HF individual and directly correlating them with neuropsychological performance remains unexplored .
Therefore, this study aims to quantitatively analyze cardio-cerebral oxygen reserve in HF patients using OS-MRI and systematically evaluate their cognitive function with the Montreal Cognitive Assessment (MoCA). By examining the correlation between changes in cardio-cerebral oxygen reserve and cognitive function, we seek to determine whether cardio-cerebral oxygen reserve can serve as an early and effective imaging biomarker for predicting the risk of cognitive decline in HF patients, thereby providing direct imaging evidence to elucidate the "heart-brain axis" mechanism underlying HF-related cognitive disorders.
NYHA classification II=IV heart failure patients and age- and sex-matched control group
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
enrolled NYHA II-IV level heart failure patients
Behavioral: breathing training
confirmed to have no ischemic heart disease by physical examination and echocardiography, will be recruited.
Behavioral: breathing training
Before MRI scanning, participant will trained to exhale and hold their breath
Cognitive function decline
The MoCA scoreless than 26 points is considered to indicate cognitive dysfunction
Time frame: Within after MRI scanning 24 hours
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Mar 2026; primary completion for Oct 2026, 7 months later.
Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 7 months is below that.
Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Yan'an Affiliated Hospital of Kunming Medical University